Follow us on:

Linkedin Facebook

GSK settles another Zantac litigation case

GSK

GSK plc (LSE/NYSE) has confirmed it has reached a confidential settlement with Boyd/Steenvoord, resolving the case filed in California state court.

The case, which was set to begin trial on 2 April 2024, will be dismissed. The settlement reflects the Company’s desire to avoid the distraction related to protracted litigation in this case.

GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.

Share on:

Latest Company News

GSK

GSK secures FDA approval for Exdensur in severe eosinophilic asthma

GSK plc has received US FDA approval for Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 and over.
GSK plc

GSK Plc secures UK approval for Exdensur in asthma and nasal polyps

GSK has announced that Exdensur (depemokimab) has received marketing authorisation from the UK MHRA for use in certain asthma and chronic rhinosinusitis with nasal polyps patients.
GSK plc

GSK RSV vaccine recommended for wider adult use, CHMP backs expansion

GSK has announced that the EMA’s CHMP has recommended broadening the indication of its adjuvanted RSV vaccine to adults aged 18 and over, with a final decision expected in February 2026.
GSK

GSK receives US FDA Orphan Drug Designation for SCLC treatment risvutatug rezetecan

GSK has announced that its B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, has been granted Orphan Drug Designation by the US FDA for small-cell lung cancer.
GSK

GSK subsidiary TESARO starts legal action over Jemperli licence dispute

TESARO, part of GSK, has filed a case in the Delaware Chancery Court claiming AnaptysBio has breached its licence agreement for the cancer treatment Jemperli.
GSK Plc

GSK Plc lifts 2025 guidance after strong Q3 sales and profit growth

GSK reported Q3 2025 sales of £8.5 billion, up 8% at constant exchange rates, driven by strong performances across Specialty Medicines, Vaccines and General Medicines.

    Latest interviews

    View all interviews 

    Company Presentations

    View all Company Presentations

    BrokersTalk

    View all Broker Talk

    FTSE 100 News

    Search

    Search

    Green News

    View all Sustainable sectors, Plcs and news  

    Q&A's

    View all Question and Answers

    Funds

    View all Funds, Market Insights and news

    UK Broker Ratings

    Hardman & Co

    Don't Miss Our News Alerts

    Subscribe Free

    Find us on:

    Linkedin Facebook

    Follow us on Social Media:

    Home X-twitter Linkedin Facebook Spotify Apple